The Impact of Anlotinib on Brain Metastases of Non-Small Cell Lung Cancer: Post Hoc Analysis of a Phase III Randomized Control Trial (ALTER0303).

CONCLUSION: Anlotinib can benefit patients with advanced NSCLC with BM and is highly potent in the management of intracranial lesions. Its special effect on BM and cerebral tissue merits further investigation. (ClinicalTrials.gov ID: NCT02388919). PMID: 32077550 [PubMed - as supplied by publisher]
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Oncologist Source Type: research

Related Links:

Publication date: Available online 30 May 2020Source: Oral Surgery, Oral Medicine, Oral Pathology and Oral RadiologyAuthor(s): Kevin C. Lee, Sung-Kiang Chuang
Source: Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology - Category: ENT & OMF Source Type: research
Publication date: Available online 30 May 2020Source: Pharmacological ResearchAuthor(s): Ling Wang, Ke Deng, Liang Gong, Liang Zhou, Sapna Sayed, Huan Li, Qi Sun, Zijie Su, Zhongyuan Wang, Shanshan Liu, Huifang Zhu, Jiaxing Song, Desheng Lu
Source: Pharmacological Research - Category: Drugs & Pharmacology Source Type: research
Publication date: Available online 31 May 2020Source: Pharmacology &TherapeuticsAuthor(s): Jie Yu, Bingling Zhong, Qingwen Xiao, Lida Du, Ying Hou, Hong-Shuo Sun, Jin-Jian Lu, Xiuping Chen
Source: Pharmacology and Therapeutics - Category: Drugs & Pharmacology Source Type: research
Publication date: Available online 31 May 2020Source: Pharmacology &TherapeuticsAuthor(s): Kevin M. Levine, Kai Ding, Lyuqin Chen, Steffi Oesterreich
Source: Pharmacology and Therapeutics - Category: Drugs & Pharmacology Source Type: research
Publication date: August 2020Source: Biomedicine &Pharmacotherapy, Volume 128Author(s): Qi Chen, Huachao Xu, Jiang Zhu, Kehai Feng, Changlu Hu
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
Abstract OBJECTIVE: Immune checkpoint inhibitors (ICIs) improve survival in patients with advanced non-small cell lung cancer (NSCLC). Clinical trials examining the efficacy of ICIs in patients with NSCLC excluded patients with untreated brain metastases (BMs). As stereotactic radiosurgery (SRS) is commonly employed for NSCLC-BMs, the authors sought to define the safety and radiological and clinical outcomes for patients with NSCLC-BMs treated with concurrent ICI and SRS. METHODS: A retrospective matched cohort study was performed on patients who had undergone SRS for one or more NSCLC-derived BMs. Two matche...
Source: Journal of Neurosurgery - Category: Neurosurgery Authors: Tags: J Neurosurg Source Type: research
In this study, to improve our understanding of the role of ATP1A1 in the malignant phenotype and pathogenesis of GSCs, we evaluated ATP1A1 expression in GBMs of different grades and in two primary GSC lines established from human GBM tissues. We evaluated the role of ATP1A1 in GSC growth, its interactions with Src, and the activation of the ERK1/2 and AKT pathways. Our results revealed that ATP1A1 acts as an oncogene in our GSC models and targeting ATP1A1/Src may suppress GSC proliferation and growth. Materials and Methods Cell Isolation and Culture Human brain GBM tissues were from pathologically confirmed surgical spe...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Conclusions This review describes how leukocyte-heparanase can be a double-edged sword in tumor progression; it can enhance tumor immune surveillance and tumor cell clearance, but also promote tumor survival and growth. We also discuss the potential of using heparanase in leukocyte therapies against tumors, and the effects of heparanase inhibitors on tumor progression and immunity. We are just beginning to understand the influence of heparanase on a pro/anti-tumor immune response, and there are still many questions to answer. How do the pro/anti-tumorigenic effects of heparanase differ across different cancer types? Does...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
This study was conducted to determine the incidence of ICH associated with anticoagulant use in adult patients with brain metastases. Consecutive patients with brain metastases occurring from 2006 to 2014 were identified from a single-institution database. Long-term anticoagulant therapy was defined as outpatient anticoagulation therapy of>  1 month. Chi-square tests and Fisher’s exact test were used to compare rates of ICH by groups. This cohort included 125 patients with brain metastases. Of these, 64 had primary of non-small cell lung cancer (51.2%). Of these patients, 12/125 (9.6%) patients developed...
Source: Medical Oncology - Category: Cancer & Oncology Source Type: research
Authors: Isgrò MA, Bottoni P, Scatena R Abstract Neuron-specific enolase (NSE) is known to be a cell specific isoenzyme of the glycolytic enzyme enolase. In vertebrate organisms three isozymes of enolase, expressed by different genes, are present: enolase α is ubiquitous; enolase β is muscle-specific and enolase γ is neuron-specific. The expression of NSE, which occurs as γγ- and αγ-dimer, is a late event in neural differentiation, thus making it a useful index of neural maturation.NSE is a highly specific marker for neurons and peripheral neuroendocrine cells. As a r...
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
More News: Brain | Brain Cancers | Cancer | Cancer & Oncology | Hemorrhagic Stroke | Lung Cancer | Neurology | Non-Small Cell Lung Cancer | Psychology | Toxicology